ASCT2 Inhibitors
1 drugsAbout ASCT2
ASCT2 (Alanine, Serine, Cysteine Transporter 2) is a transmembrane protein that transports neutral amino acids across cell membranes, influencing cellular metabolism and signaling.
ASCT2's role in amino acid transport makes it a potential therapeutic target, though currently there is no genetic evidence directly linking it to specific diseases.
ASCT2 is targeted by one FDA-approved small molecule drug, AXUMIN, developed by BLUE EARTH, with applications in an 'Other' therapeutic area.
Top ASCT2 Drugs
BLUE EARTH is the only company with an approved drug targeting ASCT2.
The single-player competitive landscape indicates high barriers to entry or limited commercial interest.
ASCT2 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ASCT2, using small molecule modality.
The lack of modality diversity suggests an opportunity to explore alternative approaches like antibodies or peptides.
ASCT2 Clinical Trials 4 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ASCT2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ASCT2 Drug Approval Timeline (2016 - 2016)
The first and only drug approval for ASCT2 was AXUMIN in 2016.
The stagnant approval timeline suggests a saturated market or challenges in developing new ASCT2-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ASCT2. A trial counts if an approved drug acting on ASCT2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.